NovoCure Ltd. (NASDAQ:NVCR)’s share price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $11.57 and last traded at $11.61, with a volume of 129,497 shares trading hands. The stock had previously closed at $12.00.

Several equities analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of NovoCure in a report on Wednesday, July 6th. Zacks Investment Research downgraded shares of NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. NovoCure currently has an average rating of “Hold” and an average target price of $28.57.

The firm has a 50-day moving average price of $11.54 and a 200 day moving average price of $12.96. The company’s market capitalization is $978.73 million.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.09. The business earned $13.10 million during the quarter, compared to analysts’ expectations of $23.65 million. On average, analysts anticipate that NovoCure Ltd. will post ($1.38) EPS for the current year.

In related news, COO Michael J. Ambrogi sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the transaction, the chief operating officer now owns 324,084 shares in the company, valued at $3,966,788.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Several institutional investors have made changes to their positions in the stock. Hartline Investment Corp acquired a new position in shares of NovoCure during the fourth quarter worth approximately $1,143,000. Century Capital Management LLC acquired a new position in shares of NovoCure during the fourth quarter worth approximately $2,970,000. Finally, Morgan Stanley acquired a new position in shares of NovoCure during the fourth quarter worth approximately $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.